LOGO.jpg
Interpace Biosciences Announces Contract for Thyroid Testing with Blue Cross Blue Shield of Florida
January 28, 2021 09:15 ET | Interpace Biosciences, Inc.
In-network status for ThyGeNEXT® and ThyraMIR® with State’s Largest Payer PARSIPPANY, NJ, Jan. 28, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (NASDAQ: IDXG) announced today that the...
LOGO.jpg
Interpace Biosciences to Host Third Quarter 2020 Financial Results Conference Call on Thursday, January 21, 2021
January 20, 2021 15:38 ET | Interpace Biosciences, Inc.
PARSIPPANY, NJ, Jan. 20, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (NASDAQ: IDXG) announced today that it will hold its third quarter 2020 financial results conference call and webcast...
LOGO.jpg
Interpace Biosciences Announces Third Quarter 2020 Financial and Business Results and Completion of $5 Million Bridge Loan
January 20, 2021 08:30 ET | Interpace Biosciences, Inc.
Third Quarter Net Revenue of $8.2 Million Up 7% vs Prior Year; Third Quarter Year to Date Net Revenue of $22.8 Million Up 14% vs Prior YearEstimates Fourth Quarter Net Revenue range of $9.0 million -...
LOGO.jpg
Interpace Biosciences Announces Executive Transition: Jack Stover to Retire as President and Chief Executive Officer Thomas Burnell Appointed as Successor
November 25, 2020 08:12 ET | Interpace Biosciences, Inc.
Parsippany, NJ, Nov. 25, 2020 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (NASDAQ: IDXG) today announced that Jack Stover, President & Chief Executive Officer, will retire effective December...
LOGO.jpg
Interpace Biosciences Receives Nasdaq Deficiency Notice Due to Delayed Filing of Form 10-Q; No Immediate Impact on Listing
November 19, 2020 16:11 ET | Interpace Biosciences, Inc.
PARSIPPANY, NJ, Nov. 19, 2020 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (NASDAQ: IDXG) on November 18, 2020 received notice from the Listing Qualifications Staff...
LOGO.jpg
Interpace Biosciences Announces Results of Seminal Clinical Validation Study for Thyroid Assays
October 26, 2020 06:30 ET | Interpace Biosciences, Inc.
 Study Demonstrates Superior Performance of ThyGeNEXT® and ThyraMIR® vs. Other Molecular Tests PARSIPPANY, NJ, Oct. 26, 2020 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (NASDAQ: IDXG)...
LOGO.jpg
Interpace Biosciences Announces Second Quarter 2020 Financial and Business Results
October 20, 2020 08:00 ET | Interpace Biosciences, Inc.
Year to Date Net Revenue of $14.6 Million Up 19% vs Prior Year; Second Quarter Net Revenue of $5.4 Million Publication of Seminal Clinical Validation Study Related to Thyroid Products ...
LOGO.jpg
Interpace Biosciences’ Audit Committee Investigation Finds Complaints Unsubstantiated
October 14, 2020 06:30 ET | Interpace Biosciences, Inc.
PARSIPPANY, NJ, Oct. 14, 2020 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (Nasdaq: IDXG) announced today that the Audit Committee of the Board of Directors has...
LOGO.jpg
Interpace Announces Acceptance of Seminal Clinical Validation Study for Thyroid Assays
July 21, 2020 06:05 ET | Interpace Biosciences, Inc.
 Podium Presentation Accepted for the American Society of Cytopathology (ASC) Annual Meeting PARSIPPANY, NJ, July 21, 2020 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (NASDAQ: IDXG)...
LOGO.jpg
Interpace Biosciences Announces First Quarter 2020 Financial and Business Results
June 25, 2020 16:59 ET | Interpace Biosciences, Inc.
First Quarter Net Revenue Improved Over 53% to $9.2 Million Launching COVID-19 Serology Testing Continues to Integrate Service Offerings and Streamline Costs Conference Call and Webcast Thursday...